Anti-TNFRSF14 antibody produced in rabbit

TNFRSF14 (tumor necrosis factor receptor superfamily, member 14) gene is localized to human chromosome 1p36.22-36.3, which contains other TNFR superfamily members. The encoded product is a single transmembrane protein composed of 283 amino acid residues. This protein is made up of a leader peptide of 36 amino acids, four TNFR-like cysteine-rich domains of which two are perfect and two are imperfect, and a small cytosolic tail. The mRNA has a wide range of tissue expression, with constitutive and predominant expression in monocytes, B and T cells. The putative molecular weight of this protein is 28kDa.

Tumor necrosis factor receptor superfamily member 14 precursor recombinant protein epitope signature tag (PrEST)

All Prestige Antibodies Powered by Atlas Antibodies are developed and validated by the Human Protein Atlas (HPA) project and as a result, are supported by the most extensive characterization in the industry.

The Human Protein Atlas project can be subdivided into three efforts: Human Tissue Atlas, Cancer Atlas, and Human Cell Atlas. The antibodies that have been generated in support of the Tissue and Cancer Atlas projects have been tested by immunohistochemistry against hundreds of normal and disease tissues and through the recent efforts of the Human Cell Atlas project, many have been characterized by immunofluorescence to map the human proteome not only at the tissue level but now at the subcellular level. These images and the collection of this vast data set can be viewed on the Human Protein Atlas (HPA) site by clicking on the Image Gallery link. We also provide Prestige Antibodies^® protocols and other useful information.

TNFRSF14 (tumor necrosis factor receptor superfamily, member 14), along with its ligand, is thought to be involved in T-cell activation and proliferation. It acts as a regulator of immunological processes, and is aberrantly expressed in multiple cancers. It confers protection to cancer cells from host autoimmune mechanisms. It is linked to human esophageal squamous cell carcinoma, and might have potential as a therapeutic target for the same. It also plays a part in the pathogenesis of inflammatory and autoimmune disorders. Studies in Chinese population show that variants of this gene are linked to risk of sporadic breast cancer.

Prestige Antibodies^® are highly characterized and extensively validated antibodies with the added benefit of all available characterization data for each target being accessible via the Human Protein Atlas portal linked just below the product name at the top of this page. The uniqueness and low cross-reactivity of the Prestige Antibodies^® to other proteins are due to a thorough selection of antigen regions, affinity purification, and stringent selection. Prestige antigen controls are available for every corresponding Prestige Antibody and can be found in the linkage section.

Every Prestige Antibody is tested in the following ways:

• IHC tissue array of 44 normal human tissues and 20 of the most common cancer type tissues.
• Protein array of 364 human recombinant protein fragments.

Solution in phosphate-buffered saline, pH 7.2, containing 40% glycerol and 0.02% sodium azide

Corresponding Antigen APREST70335

Prestige Antibodies is a registered trademark of Merck KGaA, Darmstadt, Germany

Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.